Status:
RECRUITING
Immune Profiling for Cancer Immunotherapy Response
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Conditions:
Cancer
Tumor, Solid
Eligibility:
All Genders
18+ years
Brief Summary
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) i...
Eligibility Criteria
Inclusion
- Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
- Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).
Exclusion
- Pregnant women/fetuses/neonates
- Prisoners
- Decision-impaired individuals
Key Trial Info
Start Date :
October 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2029
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT06116032
Start Date
October 3 2022
End Date
January 1 2029
Last Update
December 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756